Objective: There is a large evidence to practice gap in diabetes care with limited performance assessments that capture the full spectrum of care delivery. Our study aimed to develop a set of ambulatory diabetes quality indicators across six domains (effectiveness, safety, patient-centered, timely, equitable and efficient) to provide a broad view of quality. Design: A modified Delphi panel process was conducted. Phase I involved compiling a list of indicators through literature review and generation of patient and healthcare provider-derived indicators through interviews and surveys, respectively. Phase II involved panelists rating indicators using the Agency for Healthcare Research and Quality measure attributes on 9-point Likert scale, attending a face-to-face meeting followed by re-rating, and final ranking. Setting: This study was conducted across five adult academic medical centers affiliated with the University of Toronto. Participants: A multi-disciplinary Delphi panel (n = 16) including patients was assembled. Main Outcome measure: For indicator advancement for ranking, ≥75% of panelists' responses in the top tertile (between 7 and 9) with a median composite score of ≥7 was required. Results: There were 202 indicators included in the Delphi panel process including 171 from a comprehensive literature review, 14 from patient interviews, and 17 from healthcare provider surveys. Following the first round, 40 indicators proceeded directly to ranking, while 162 indicators were re-rated and distilled down to 12 for ranking. In the final ranking round, the 52 indicators were reduced to 35 including 13 effective, 10 safe, 6 patient-centered, 1 equitable, 3 efficient and 2 timely indicators. Conclusion: Thirty-five selected indicators developed with broad stakeholder engagement can be used to monitor quality in diabetes care.
Introduction
Diabetes is a complex chronic condition associated with significant complications including adult-onset blindness and renal failure [1, 2] . Despite evidence that optimal management of diabetes can prevent or delay progression of complications [3] [4] [5] , a large evidence to practice gap remains [6, 7] . Limited meaningful data to assess practice patterns pose a significant challenge towards improving diabetes care [8] .
The Institute of Medicine (IOM) defines quality in healthcare as having six domains: effectiveness, safety, patient-centeredness, equity, efficiency and timeliness [9] . Yet, the majority of diabetes quality assessments cite metrics only within the 'effectiveness' domain, such as achieving glycemic control and screening for complications [6, 8] .
There is discordance between reported metrics and stakeholder priorities; patients with diabetes prioritize patient-centeredness and safety above other domains, while providers prioritize effectiveness [10] . Engaging patients in setting priorities and incorporating patientreported outcome measures in quality assessments have increasingly been recognized to provide a broad view of quality [11] [12] [13] .
Quality indicators are used by healthcare organizations to monitor performance and improve healthcare delivery [14] . However, there is currently no standardized set of quality indicators that incorporates all domains of quality and one that is developed with patient involvement for diabetes care. The objective of this study was to establish a set of indicators to monitor quality of specialty ambulatory diabetes care across the six IOM domains with a focus on patient engagement.
Methods

Setting and scope
This study was conducted across five adult academic medical centers affiliated with the University of Toronto between July 2013 and September 2015. The scope was to develop a set of quality indicators for specialty ambulatory adult diabetes clinics. Phase I involved generation of candidate indicators from three sources (literature review, patient interviews, and healthcare provider survey) and Phase II involved three rounds of a modified Delphi panel process to select a set of quality indicators for diabetes care ( Fig. 1) [15] . The Centre for Effective Practice (CEP), was engaged to support the execution of both Phase I and II. Ethics approval was obtained from the Sunnybrook Health Sciences Centre research ethics board, Toronto, Canada.
Phase I-Generation of the candidate list of indicators
Comprehensive literature review A comprehensive search of published literature for existing diabetes quality indicators was conducted using Ovid MEDLINE database by a medical librarian. Published literature MeSH search terms used were: 'Diabetes Mellitus, Type 1', 'Diabetes Mellitus, Type 2', 'Quality Indicator, Health Care', 'Quality of Health Care', 'Outcome and Process Assessment (Health Care), 'Patient Outcome Assessment', 'Treatment Outcome',' 'Quality Assurance, Health Care,' 'Benchmarking,' 'Clinical Audit,' 'Medical Audit,' 'Nursing Audit', 'Total Quality Management' and 'Utilization Review'. In addition, the following terms were used with appropriate truncation and wildcard symbols to search publication titles and abstract fields: 'indicator', 'quality standard', 'quality metric', 'quality measure', 'quality report', 'care evaluation', 'performance measure', 'benchmark', 'balanced scorecard' and 'logic model'. Only English language indicators published between June of 2009 and June of 2014 were included to ensure that the list was representative of contemporary information.
A keyword search of electronic grey literature (defined as 'that which is produced on all levels of government, academics, business and industry in print and electronic formats, but which is not controlled by commercial publishers' [16] ) was also performed to locate organizations relevant to the topic, and their material was examined to identify additional indicators. A list of websites for organizations that develop or report on indicators was used to extract existing quality indicators for the management of Type 1 and Type 2 diabetes. The following terms were used in Google: 'diabetes', 'indicator(s)', 'quality measure(s)', 'benchmark(ing)', 'balanced scorecard', 'balanced scorecard', 'performance measures', 'performance measurement'. The first five pages of results were examined unless new relevant results were found, and then additional pages were examined until a page of results presented no additional relevant results.
Indicators that focused on patients under 18 years of age and population-based indicators such as incidence and prevalence were excluded. To be considered for inclusion, the studies needed to outline the process used to develop the indicators, or reference the supporting evidence [17] .
Patient interviews
Qualitative semi-structured one-on-one interviews with patients with diabetes using maximum variation sampling across five academic hospitals at the University of Toronto were conducted as described previously [18] . Briefly, representative patients with diabetes were interviewed to obtain patient perspectives on quality of care in diabetes clinics. Data from the interviews was analyzed using a directed content analysis approach for common themes with the six IOM quality domains serving as the a priori framework [19, 20] . These themes were compared to indicators found through the literature review and new indicators were developed to address any identified gaps. Member checking for indicator validity was conducted through two focus groups of patients who participated in the initial interviews.
Healthcare provider survey A pre-Delphi healthcare provider survey was sent via e-mail using FluidSurveys™ (an online survey software) to all endocrinologists and certified diabetes educators affiliated across five academic hospitals. The purpose was to collect feedback on the candidate list of indicators generated from the literature search and patient interviews, solicit additional indicators to fill any gaps, and collect Delphi panel nominations. A secondary objective was to ascertain feedback on considerations for selection of diabetes quality indicators.
Phase II-Modified Delphi panel process
Two study investigators conducted independent reviews of the list of indicators generated from Phase I. Inclusion criteria were indicators related to adults with Type 1 or 2 diabetes, the management of diabetes, and relevant to ambulatory care. Exclusion criteria were indicators that were duplicate, indicators out of specialists' clinical scope (i.e. screening for diabetes) or setting scope (i.e. inpatient quality indicators). Indicators where there was disagreement regarding exclusion were reviewed independently by a third investigator for consensus. Included indicators were categorized within each IOM quality domain independently by two study investigators and discrepancies were resolved by consensus. Prior to circulating the indicators to the Delphi panel, the set was appraised by five study investigators and minor revisions of the wording of the indicators were conducted to be measurable when necessary.
A modified Delphi panel process was used to determine a set of indicators for use in ambulatory specialty diabetes care settings across six IOM quality domains (Supplementary Material 1) [21] . A Delphi panel is an iterative multistage process designed to combine opinion into group consensus [21] . The process integrated key features from the literature on developing healthcare quality indicators and involved two rounds of rating and one final round of ranking using both anonymous surveys and in-person meeting techniques [14, 15] . The panel was selected through a combination of a nomination process, invitation and a stakeholder mapping exercise.
Round 1
For round 1, a complete narrowed list of indicators was circulated to the panelists through FluidSurveys™. Panelists were asked to rate each indicator against the four Agency for Healthcare Research and Quality's (AHRQ) quality measures attributes on a 9-point Likert scale where 1 indicates strong disagreement and 9 indicates strong agreement (Supplementary Material 2) [22] . Panelists lacking the required proficiency to judge a particular indicator (e.g. patient judging efficacy of pharmacological treatments), could denote it as 'uncertain/equivocal' (5 on the Likert scale). Panelists were also provided with the opportunity to comment on each indicator and suggest additional indicators for consideration in the next round of ratings. To support the rating process, panelists were provided with: project overview summary, rating instructions, complete list of all indicators, and relevant guidelines and published articles on diabetes quality indicators [5, [23] [24] [25] .
Panelists' ratings were weighed across the four AHRQ criteria in the following manner: importance of the measure (40%); scientific soundness: clinical logic (20%); scientific soundness: measurement properties (20%); feasibility (20%) to determine the composite score for each indicator. Indicator inclusion criteria after round 1 and 2 rating were: ≥75% panelists' responses within the top tertile (7-9) and a median composite score of ≥7. Indicator exclusion criteria were: ≥75% panelists' responses within the bottom tertile (1-3). Indicators meeting the inclusion criteria in round 1 or 2 did not require re-rating and were automatically included in round 3 (ranking). Indicators meeting the exclusion criteria did not require rerating and were excluded.
Round 2
For round 2, a structured, five hour facilitated in-person Delphi panel meeting was conducted two weeks after round 1 to discuss indicators for which consensus was not obtained and to present the evidence pertaining to the indicators. Median, minimum and maximum scores were circulated for these indicators prior to the meeting for comparison of individual panelists' scores to the group scores. The discussion was moderated by a study researcher and an independent facilitator. During the meeting, additional indicators were solicited to identify key gaps in the existing list of indicators. Panelists were asked to rerate indicators following the meeting in round 2, and indicators that met inclusion criteria were included in round 3.
Round 3
For round 3, panelists ranked the remaining indicators within each quality domain. From this ranking, median and interquartile ranges for the indicators were calculated within each quality domain. Indicators were reviewed in order of highest to lowest median ranking by an expert committee to enable selection of indicators for inclusion.
Results
Phase I
Comprehensive literature review-derived indicators The literature search generated 51 articles, from which 864 indicators were extracted. Following removal of duplications and out of scope indicators, 171 were included in the first round of the Delphi panel from the literature review.
Patient interviews-derived indicators
The patient interviews generated 14 additional indicators (Supplementary Material 3). The median age of participants (n = 46) was 50 (53% male, 57% had Type 2 diabetes) with a mean duration of diabetes of 14 years.
Pre-Delphi healthcare provider survey-derived indicators
The pre-Delphi survey was completed by 50 providers (49% response rate). The survey was completed by 22 (44%) certified diabetes educators (registered nurses, dieticians, nurse practitioners), 20 (40%) endocrinologists, and 8 (16%) did not indicate their profession. On average, respondents had worked in healthcare for 19.2 years (SD = 11.5) with 67% (SD = 22.1) of their time spent on clinical work. The survey yielded an additional 17 indicators for consideration in the Delphi panel process (Supplementary Material 4) . Qualitative feedback from the healthcare provider survey included having indicators that assess coordination of care (n = 6) and setting and achieving individualized targets to consider the complexity of the patient (n = 4). When specifically asked about the best method to assess whether glycemic control is being adequately managed as a quality indicator, 33 (67.3%) endorsed setting and achieving individualized targets for patients, 7 (14.3%) suggested other methods (e.g. threshold-based, in conjunction with percentage in target of selfmonitoring of blood glucose [SMBG] values to eliminate frequent hypoglycemic and hyperglycemic variation), 6 (12.2%) preferred a threshold-based approach (e.g. 'percentage with most recent glycated hemoglobin [HbA1c] ≤7%'), and 3 (6.1%) preferred a relative change (e.g. 'percentage with a X% reduction in HbA1c'). There were 202 indicators generated from Phase I for inclusion in Phase II (Fig. 1) 
Phase II
The Delphi panel comprised of 16 stakeholders including 4 (25%) patients, 1 (6.3%) dietician, 1 (6.3%) diabetes program manager, 3 (18.8%) diabetes nurses, 1 (6.3%) pharmacist, 1 (6.3%) government administrator in diabetes care, 4 (25%) endocrinologists and 1 (6.3%) primary care physician. The attrition rate was 2 (12.5%); two panelists dropped out following completion of the first round.
Round 1
Following round 1 of rating, 40 (19.8%) indicators met consensus to include and advance to round 3, none were excluded, and 162 (80.2%) indicators did not reach consensus and were therefore included in round 2 for re-rating following the in-person meeting (Fig. 1 ).
Round 2
In round 2, 12 (7.4%) indicators met consensus to include and therefore a total of 52 (25.7% of the original 202) indicators advanced to round 3 for ranking. Qualitative review of discussion notes from panel meetings revealed that the majority of panelists agreed with the preDelphi healthcare survey respondents that the best method to assess whether glycemic control is being managed is setting and achieving individualized targets. From the panel meeting, 17 new indicators were generated based on discussion (Supplementary Material 5) . A postmeeting evaluation was conducted through anonymous written evaluations from the participants reported that their opinions were valued, and that the process was fair and unbiased.
Round 3
Following round 3 ranking, indicators considered for inclusion for the final set were based upon median ranking (and interquartile range) by the Delphi panel and ensuring there was no overlap with other highly ranked indicators. The final list included 35 indicators with representation from each quality domain: 13 effectiveness, 10 safe, 6 patient-centered, 1 equitable, 3 efficient, and 2 timely indicators ( Table 1) . Out of the final 35 indicators, 5 (14.3%) were patient-derived, 4 (11.4%) were derived from the healthcare provider survey, 3 (8.6%) were derived from the Delphi panel and the remaining 23 (65.7%) were from the literature.
Discussion
Through a structured modified Delphi panel process, using broad stakeholder engagement that included patients, a set of 35 indicators were identified to measure quality in diabetes specialty care. The set of quality indicators selected in this study has representation of all six IOM domains of quality [9] .
While other sets of quality indicators in diabetes care have been described, they have largely focused on the 'effectiveness domain' with limited emphasis of other quality domains and incorporation of the patient perspective [26] [27] [28] [29] . A set of performance measures Percentage of women of childbearing age with diabetes not planning a pregnancy who are offered advice on family planning
The number of women in the denominator offered advice on family planning
The number of women with diabetes not planning a pregnancy 14 7 7.0 2.8 7.8
Percentage of patients with co-prescriptions to be avoided, e.g. of statins with macrolides, diuretic, ACEinhibitor with potassium or nonsteroidal antiinflammatory drug (NSAID), metformin with glibenclamide, etc.
Number of patients with co-prescriptions to be avoided, e.g. of statins with macrolides, diuretic, ACE-inhibitor with potassium or NSAID, metformin with glibenclamide, etc. Percentage of patients with diabetes followed by diabetes specialist/endocrinologist for whom the specialist has Number of patients with diabetes followed by diabetes specialist for whom the specialist has provided written 13 3 2.0 2.0 8.0 [28] . In comparison, our set of indicators has representation of all six domains of quality. We also incorporated patients and multi-disciplinary healthcare providers during the development phase. Our set of quality indicators includes patientreported experience measures and other patient-centered elements such as counseling and setting individualized targets, as it is increasingly being recognized that patients provide meaningful insight to defining quality of care [12, 13, 30, 31] . In addition, a cited limitation in the Martirosyan et al. paper is that they included all-or nothing treatment targets which has been suggested to make poor performance measures, including setting the glycemic target for all patients at a HbA1c of 7%, which may not be appropriate for individuals who are older, or who have comorbid conditions [5] . Our stakeholders supported the need for individualized targets for glycemic control, which aligns with recent changes in guideline recommendations to set personalized goals for diabetes care [5, 32] . With our set of indicators, we will be able to obtain a more comprehensive view of quality of diabetes care [4, 33, 34] . Our study has a number of strengths to note. The methodological approach was systematic and aligns with Campbell's factors influencing whether indicators are rated valid in the Delphi technique [14] . We had a diverse multi-disciplinary Delphi panel that also included patients and government personnel. Secondly, we included indicators based both on published and grey literature to ensure our indicator list was comprehensive. We provided opportunity for broad input to identify any gaps using the pre-Delphi survey, patient interviews and Delphi panel discussion and generated 'novel' indicators not reflected in the existing literature. Our final list of quality indicators reflects the broad view of quality within healthcare. Thirdly, we used a validated rating scale based on the AHRQ quality measure attributes and used the feedback from each round to inform the selected indicators [22] . We also used a combination of in-person discussion and anonymous ratings, which allowed securing the benefits of group decision-making while insulating the process from dominant members.
However, some limitations associated with our modified Delphi panel process need acknowledgment. First, the review of literature was not a systematic process but was a targeted comprehensive review of both published and grey literature. Secondly, our predelphi healthcare provider survey had a modest survey response rate. Thirdly, the scope of the study was to measure quality of diabetes care in specialty diabetes clinics, therefore generalizability to other settings (such as primary care) may not be applicable. These set of indicators would benefit from validation in different settings. Nevertheless, the methodology used and list of candidate indicators can be applied to other healthcare contexts.Fourthly, while we adhered to a rigorous method, the Delphi panel methodology is opinion-based and there may be different recommendations based on the same evidence. We took efforts to promote generalizability by including a multi-disciplinary panel from different clinics including patients and a rigorous process to combine scientific evidence with expert opinion. Finallyy, assessing the feasibility and applicability of using these quality indicators in real-life health contexts will be required.
The next steps are to develop operational definitions of the set of indicators and pilot implementation in healthcare delivery contexts to monitor quality in diabetes care. Further efforts will be directed to assess the feasibility of using the set of quality indicators to drive continuous quality improvement with associated benchmarks as part of a balanced scorecard, which is increasingly being used by healthcare organizations to improve care delivery [35] . A recent large multinational randomized controlled study from Europe demonstrated that providing benchmarked feedback to physicians on their set of diabetes quality indicators improved clinical outcomes for patients [36] . Henriksen et al. recently reported that implementing a set of quality indicators as part of a balanced scorecard at a large academic health center resulted in significant improvement in their performance metrics [37] . Developing effective systems that enable reporting quality indicators across all domains of quality with incorporation of patient-reported outcome measures can support in driving continuous quality improvement efforts and transform healthcare delivery for patients.
Conclusions
We developed a set of quality indicators to monitor diabetes care with extensive stakeholder engagement that included patients and a broad view of quality. This set of indicators can be adapted and adopted by other programs to monitor and improve upon safe, effective, timely, efficient, equitable and patient-centered care for people living with diabetes.
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